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There is uncertainty regarding possible benefits of screening for depression in family 
practice, as well as the most effective treatment approach when depression is identified. 
Here, we examined whether screening patients for depression in primary care, and then 
treating them with different modalities, was better than treatment-as-usual (TAU) alone. 
Screening was carried out for depression using the 9-item Patient Health Questionnaire 
(PHQ-9), with a score of ≥10 indicating significant depressive symptoms. PHQ-9 scores 
were given to family physicians prior to patients being seen (except for the Control group). 
Patients (n = 1,489) were randomized to one of four groups. Group #1 were controls 
(n = 432) in which PHQ-9 was administered, but results were not shared. Group #2 was 
screening followed by TAU (n = 426). Group #3 was screening followed by both TAU and 
the opportunity to use an online cognitive behavioral therapy (CBT) treatment program 
(n = 440). Group #4 utilized an evidence-based Stepped-care pathway for depression 
(n = 191, note that this was not available at all clinics). Of the study sample 889 (60%) 
completed a second PHQ-9 rating at 12 weeks. There were no statistically significant dif-
ferences in baseline PHQ-9 scores between these groups. Compared to baseline, mean 
PHQ-9 scores decreased significantly in the depressed patients over 12  weeks, but 
there were no statistically significant differences between any groups at 12 weeks. Thus, 
for those who were depressed at baseline Control group (Group #1) scores decreased 
from 15.3 ± 4.2 to 4.0 ± 2.6 (p < 0.001), Screening group (Group #2) scores decreased 
from 15.5 ± 3.9 to 4.6 ± 3.0 (p < 0.001), Online CBT group (Group #3) scores decreased 
from 15.4 ± 3.8 to 3.4 ± 2.7 (p < 0.01), and the Stepped-care pathway group (Group #4) 
scores decreased from 15.3 ± 3.6 to 5.4 ± 2.8 (p < 0.05). In conclusion, these findings 
from this controlled randomized study do not suggest that using depression screen-
ing tools in family practice improves outcomes. They also suggest that much of the 
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inTrODUcTiOn
Depression is recognized as one of the most prevalent and costly 
conditions in society, occurring in approximately 10–20% of 
patients attending their family care physicians (1). However, it 
has been estimated that less than half are adequately recognized 
and treated (2). Depressed patients have higher rates of mor-
bidity and mortality for a given level of medical illness (3–7). 
More specifically, depression occurs commonly in patients 
presenting to primary care physicians (8) and is frequently not 
diagnosed (9–11). This is important since primary care patients 
with depression have higher levels of morbidity and mortality, 
as well as greater health care costs, than similar patients without 
depression (12, 13). Thus, it is important to identify depression 
occurring in primary care patients, as well as treat it more 
effectively.
One suggested method to increase depression recognition is 
to screen for this in all adults attending primary care (14, 15) 
and/or looking more intently for the presence of depression in 
those with specific medical conditions (16, 17). Indeed, a recent 
US Preventive Services Task Force Recommendation was that 
screening for depression should occur in primary care for all 
adults who have not been screened previously (18). To assist this, 
it has been proposed that standardized depression screening tools 
be used for this in primary care (19). There are tools designed 
to help with patients screening, including patient centered-ones 
(20), and to also assist physicians determine appropriate antide-
pressants to use (21). One of the most widely used screening tools 
is the 9-item Patient Health Questionnaire (PHQ-9), a depression 
screening measure specifically developed for use in primary care 
(22), and widely validated in primary care (23–25).
However, it should be noted that, in contrast to the US 
Preventive Services Task Force Recommendation, the Canadian 
Task Force on Preventive Health Care specifically recommended 
that screening for depression should not occur in primary care 
(19, 26). One of the reasons for such conflicting advice may be 
the relative lack of randomized controlled studies that can help 
clarify the potential benefits (or otherwise) of screening for 
depression in primary care. Another possible reason for these 
opposing recommendations may be the relative lack of access to 
treatment options for depressed patients when they are identified 
by primary care physicians.
Additionally, and the major focus of the present study was to 
try and help clarify the most appropriate treatment option when 
depression is identified. This includes previous development of 
a variety of Stepped-care pathways, which have been developed 
for use in primary care. Stepped-care treatment models usually 
include both medication and psychosocial interventions and 
may improve outcomes for depression in primary care (27–33). 
However, such programs may be difficult to implement, can be 
resource and staff intensive, and the specific components of indi-
vidual programs can vary widely (34, 35). Furthermore, not all 
studies have found statistically significant benefits from Stepped-
care pathways (36, 37), and it remains somewhat uncertain which 
components are most effective. Several primary care practice 
characteristics can also significantly influence the quality of 
care provided to patients with depression and comorbid chronic 
conditions (38). Thus, while it is generally believed that effective 
treatment of depression decreases subsequent primary care 
visits (39), the success of any programs may be dependent upon 
perceptions of the best methods to achieve successful outcomes, 
and these in turn may differ between primary care physicians and 
their patients (40).
Nonetheless, despite uncertainty regarding the most effica-
cious components of a Stepped-care pathway, it is generally 
accepted that cognitive behavioral therapy (CBT) is an effec-
tive component of treatment of depression in primary care 
(41). One issue with the delivery of CBT has been access to 
appropriately trained therapists, and the availability of online 
versions has helped ameliorate this issue. A widely used free 
online CBT program is MoodGym, and its clinical benefits 
have been reported in primary care (42, 43), where it has been 
found to be as acceptable for most patients as face-to-face 
therapy (44). Such internet-based treatments are scalable and 
cost-effective (45), potentially making them widely available 
in primary care (46). Additionally, while it appears that online 
CBT is effective (47), other therapies may also be effectively 
delivered online (48). It should be noted, however, that while 
online psychotherapy programs are useful, they seem to be most 
effective when combined with face-to-face guided support (49). 
Indeed, a consistent finding from online studies is that such a 
“guided” approach usually has much higher retention rates 
and better outcomes (50–52). Nonetheless, the practicality of a 
“guided” approach in family practice may be limited because of 
the resources required.
In summary, current guidelines vary in whether they recom-
mend screening for all adult patients attending a primary care 
center. Second, there are differences in treatment approaches 
recommended when primary care patients are identified as 
being depressed. To enhance understanding in this area, we 
carried out a double-blind randomized study in which con-
secutive attendees at family practice sites were offered the 
option of completing a PHQ-9 rating scale on an electronic 
tablet while they were waiting for their physician, with follow-
up ratings at 6 and 12 weeks for those who were depressed, and 
12  weeks only for those who were not depressed at baseline. 
After informed consent, patients were randomized to one of 
four groups: (1) control; (2) treatment-as-usual (TAU); (3) 
depression seen in primary care spontaneously resolves and do not support suggestions 
that more complex treatment programs or pathways improve depression outcomes in 
primary care. Replication studies are required due to study limitations.
Keywords: depression, cognitive behavioral therapy, pathway, suicide, adult, mental illness, family practice, 
primary care
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online CBT program (MoodGym) (43, 44); and (4) a detailed 
Stepped-care pathway.
Based on the existing literature, it still remains uncertain 
whether or not interventions, particularly CBT or a Stepped-care 
pathway, improved depression outcomes compared to TAU. We 
are not aware of a previous similar randomized controlled study 
in primary care. Secondary hypotheses are related to the impact 
of screening itself and the frequency of onset of new cases of 
depression during the study period.
MaTerials anD MeThODs
ethical consideration
This study was approved by written consent from the Health 
Research Ethics Review Board at the University of Alberta 
(Pro00038495) for adults aged 18 who were cognitively capable 
of giving informed consent. Approval was first given on 30th 
July 2013 and then included some small changes. The protocol 
presented in the present paper includes all approved changes.
Note that if any subject expressed suicidal thoughts or feel-
ings at any time, in either written form or verbally, the patient’s 
physician was immediately notified. This study was conducted 
according to International standards of Good Clinical Practice 
(International Conference on Harmonization guidelines), the 
Declaration of Helsinki (2008 amendment, Seoul, Korea), appli-
cable government regulations and Institutional research policies 
and procedures. It was registered with Clinical Trials database, 
http://ClinicalTrials.gov Identifier: NCT01975207.
study Flow
After a patient had registered for their appointment with their 
primary care physician, they were informed there was a study tak-
ing place and were given information about this. If they expressed 
interest, they were given information, and if they wanted to pro-
ceed they then signed an informed consent form, and also had 
the opportunity to discuss the study with a member of the study 
team. Only at this point, they were included in the study, given a 
unique study number, and were able to complete the PHQ-9 on 
an electronic tablet (Figure 1).
Primary study hypotheses
The primary study hypothesis was that active treatments for 
depressed primary care patients (defined as those patients who 
scored ≥10 on PHQ-9 score following screening) would have 
lower scores for depression at 12 weeks compared to both controls 
and those who only received TAU. Thus, it was hypothesized that 
PHQ-9 scores would decrease to a statistically significant greater 
degree at 12 weeks in Group #3 (Online CBT Treatment + TAU) 
and Group #4 (Stepped-care pathway) compared to Group #1 
(Screening Control) and Group #2 (TAU). The detailed descrip-
tions of each of these Groups are as follows:
• Group #1, Screening Control group: scores were not communi-
cated to the patient or their physician, unless they indicated a 
suicide risk (utilizing predetermined criteria).
• Group #2, TAU group: those who scored ≥10 on the PHQ-9 
were informed of this, and the score was documented, and 
both the patient and their physician were notified of their 
score. In Group #2 treatment was up to the physician and 
was TAU.
• Group #3, Online CBT Treatment +  TAU group: those who 
scored ≥10 on the PHQ-9 were informed of this, and the 
score was documented, and both the patient and their physi-
cian were notified of their score. In addition to TAU, patients 
were also informed about a free online CBT program, 
MoodGym (43, 44). They were encouraged to use it, given 
a unique log-in number, and were given some information 
about previous publications suggesting clinical efficacy of 
this program.
• Group #4, Stepped-care pathway: those who scored ≥10 on the 
PHQ-9 were informed of this, and the score was documented, 
and both the patient and their physician were notified of their 
score. In Group #4, treatment followed a specific Stepped-care 
pathway, in which all clinic physicians and therapists were 
trained. This was based on current research literature and had 
been used previously (53, 54). More details of the Stepped-care 
pathway are given below.
secondary hypotheses
There were additional secondary study hypotheses.
• That screening for depression would lead to lower scores in 
all groups when the presence of significant depression scores 
was supplied to physicians (Groups #2, #3, and #4) compared 
to the controls (Group #1), where this information was not 
supplied to either the patient or physician.
• That the spontaneous rate of new depression over the 12-week 
period would be consistent with the existing literature (55).
PhQ-9 item
To measure depression, we used the PHQ-9, a specific depres-
sion screening measure developed for use in primary care, 
which has since been widely validated (22–25). A score of ≥10 
on the PHQ-9 indicates the presence of clinically significant 
depressive symptoms. In the present study, those who scored 
≥10 on the PHQ-9 were considered depressed. Previously, 
research has suggested that scores of 10–14 are consistent with 
mild depression, scores of 14–20 are consistent with moder-
ate depression, and scores of >20 are consistent with severe 
depression (22–25).
A recent study carried out a meta-analysis, meta-regression, 
moderator, and sensitivity analysis of screening clinical utility of 
the PHQ-9 in primary care from over 40 studies involving nearly 
30,000 people (56). The authors reported that the sensitivity for 
the PHQ-9 using a cut-off point of 10 was 81% (95% CI 72–89), 
and the specificity was 85% (95% CI 81–89). The authors sug-
gested that the PHQ-9 is appropriate for screening but should not 
be used to confirm a clinical diagnosis.
In the present study, patients completed PHQ-9 questionnaire 
while waiting to see their physician. All patients were informed 
they would be followed up by telephone. In the follow-up tel-
ephone calls, the PHQ was read to the patient during this phone 
call and scored according to their answers. A similar approach has 
been used in previous research (57).
FigUre 1 | Patient flow during study. This shows the flow of patients who were randomized to each of four groups. All patients were followed up by telephone 
at 12 weeks. For those patients whose score was 10 or more on the 9-item Patient Health Questionnaire (PHQ-9), there was an additional telephone follow-up at 
6 weeks.
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stepped-care Pathway
The Stepped-care pathway used in the present study was previously 
developed in Calgary, AB, Canada, utilizing updated research 
evidence and had been successfully utilized in 158 patients in an 
open-label study in 5 primary care locations during the period 
2010–2011 (53, 54). In this previous open-label study, patients 
who scored 10–14 on the PHQ-9 (n = 61) were assigned to the 
watchful waiting level of intervention, patients who scored 15–19 
(n = 54) were assigned to the moderate intervention level, and 
patients who scored 20 or higher (n = 43) were assigned to the 
high intervention level. Successful completion of the pathway was 
defined as scoring in the non-clinical range (<10) on the PHQ-9. 
The overall 6-month successful completion rate was 56%, and the 
mean reduction in PHQ-9 scores was −8.29 (SD =  6.03). At a 
3-month follow-up after successful completion of the pathway, 
80% of the patients assessed continued to score in the non-clinical 
range on the PHQ-9 (53, 54). The same methodology was utilized 
in the current study in Group #4, and training was given to all 
involved with providing this Stepped-care pathway.
In the present study, for those patients whose PHQ-9 scores 
were in the range 10–14 there was an initial period of “watch-
ful waiting,” with a set follow-up appointment in 4  weeks and 
targeted self-management information. There were also specific 
clinical interventions for those whose scores were 15 or more. 
This intervention included additional visits, self-management 
information, medications prescribed according to guidelines, 
outside referral options, including a psychiatry consultation 
if they have non-response to medication within 6  weeks. It is 
important to note that additional resources were provided to 
those patients who were depressed and were randomized to 
Group #4, and this included increased availability of cognitive 
behavioral therapists.
Data security and Data collection
Collection of all data was on dedicated electronic tablets and 
was compliant with the local and international requirements 
for data collection. No personal information was collected 
(including age or gender), only the patient study number and 
Alberta Health Care Number. The Alberta Health Care Number 
cannot be linked to an individual, as this information is stored 
in a separate database to which the investigators had no access. 
It was collected to allow potential future anonymous analysis 
of health care utilization. Electronic data were transmitted in 
an encrypted manner over the internet. As soon as patient data 
were transmitted, neither the participant nor the study staff had 
any further access to that (or any other) information. It was 
not possible for any patient or study personnel to view their 
information, or anyone else’s until the study was complete. All 
data were stored in an encrypted manner by an independent 
organization that was authorized to maintain such information. 
At the end of the study, anonymized data were available to the 
research staff to analyze.
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randomization and statistical analysis 
Plan
Randomization was carried out at both a clinic and day level. 
There were two clinics involved, and one of these was able to enter 
patients into Group #4 (Stepped-care pathway). Therefore, in one 
clinic, patients were randomized to one of four groups (Groups 
#1–4) whereas in the second clinic, they were only randomized 
to one of three groups (Groups #1–3). This is the reason that the 
number of patients entered into Group #4 was lower than in the 
other three groups. Additionally, the randomization process was 
not done at an individual level but for an entire day at a clinic. 
This is because all communication was carried out in the waiting 
room and we did not want patients to hear about something being 
offered to one patient, when they would be offered something 
different. Therefore, the numbers in each group could not be per-
fectly matched since they depended upon the number of patients 
who came to a clinic on the days when that particular group was 
being offered.
For statistical analysis, the change in PHQ-9 was the primary 
outcome variable. Statistical analysis was carried out in R, version 
3.1.0. In a previous study, there was a decrease of only 2 points in 
the PHQ-9 at 6 weeks and 6 months when no specific treatment 
was given (58). In comparison, use of the Depression Pathway 
for treatment in a pilot study led to a mean decrease in PHQ-9 of 
10 points (from a mean baseline of 16) in those who completed 
the Treatment Pathway (53, 54). From pilot data carried out with 
the Stepped-care pathway, it was anticipated that 70% of patients 
would take part again at 12 weeks (53, 54). Additionally, based 
on this pilot research, we estimated that approximately 70% of 
subjects would have follow-up data.
Therefore, we estimated that in the completer groups, the 
mean decrease in PHQ-9 scores in the TAU group (Group #2) 
would be 2 points compared to a mean decrease in PHQ-9 
scores in the Treatment Pathway group of 10 points (Group #4). 
A power analysis suggested that, with a 95% confidence level, the 
sample size needed was 32 per group. The anticipated number of 
patients who score at least 10 on the PHQ-9 will therefore need 
to be 45 in each group, on the assumption that 70% of patients 
will complete the 12-week assessment period. This would give a 
completer analysis of 32 patients per group. If 10% of patients 
were depressed, this would require a total recruitment of 450 in 
each of the four groups, for a total recruitment of 1,800 during 
the study period, which therefore was the number of patients we 
targeted for recruitment.
Analysis was carried out utilizing Wilcoxon rank paired 
tests comparing median scores. The Wilcoxon signed-rank test 
was used to test within group comparisons while the Wilcoxon 
rank-sum test was used to test between group medians. All results 
compared baseline scores to the scores at 12 weeks.
resUlTs
This study was carried out at two different clinics containing a 
total of 18 primary care physicians. During the study recruit-
ment period from November 2013 to December 2014, a total 
of 1,489 patients were recruited into the study. Because patients 
would frequently attend several times at the same clinic during 
the 6-week periods we spent at each clinic, we were not able to 
measure the actual number of patients who were potentially eli-
gible for the study. As noted previously, as only one of the clinics 
agreed to take part in the Stepped-care pathway, the numbers 
of patients randomized to the Stepped-care pathway (Group #4) 
were lower than the other groups. A total of 432 patients were 
randomized to the Control group (Group #1), 426 patients were 
randomized to screening followed by TAU (Group #2), 440 
patients were randomized to TAU plus online CBT (Group #3), 
and 191 were randomized to the Stepped-care pathway (Group 
#4). Of these patients, approximately 15% of each group were 
depressed at baseline (PHQ-9 score ≥10) (Figure  2). A total 
of 889 patients (60%) of patients had a follow-up at 12 weeks, 
although this percentage varied between groups (Figure  2). 
Although not reported separately, the results did not change 
when controlling for site.
In terms of depression outcomes, at baseline there were 54 
(10.0%) depressed patients in the Control group, 48 (11.3%) 
depressed patients in the Screening group, 29 (6.6%) depressed 
patients in the Online CBT group, and 15 (7.9%) depressed 
patients in the Stepped-care pathway. There were no statistically 
significant differences in baseline PHQ-9 scores between these 
groups of depressed patients.
For all of the groups, there were statistically significant changes 
in PHQ-9 scores from baseline to 12 weeks (Figure 3) for Groups 
#1 and #2, but not for the treatment interventions, Groups #3 and 
#4. Thus, in the Control group (Group #1), this changed from 
a mean score of 4.6 ±  5.0 to 3.6 ±  4.3 (p <  0.001), and in the 
Screening group (Group #2), this changed from a mean score of 
4.8 ± 4.9 to 4.3 ± 4.7 (p < 0.05). In the online CBT and treatment-
as usual group (Group #3), this changed from a mean score of 
4.1 ± 4.4 to 3.6 ± 4.4 (p = 0.06), and in the smaller Stepped-care 
group (Group #4), this changed from a mean score of 4.8 ± 5.5 to 
4.1 ± 4.9 (p = 0.27).
In contrast, there were marked changes in mean PHQ-9 
scores for those who were depressed at baseline. While the 
results showed that there were no statistically significantly 
differences at baseline between the four groups in terms of the 
means scores for those who had a PHQ-9 score ≥10 (Figure 4), 
in all groups there was a very marked drop in mean PHQ-9 
scores at both 6 and 12 weeks (Figure 4). Control group (Group 
#1) scores decreased from 15.3 ± 4.2 to 4.0 ± 2.6 (p < 0.001), 
Screening group (Group #2) scores decreased from 15.5 ± 3.9 
to 4.6 ± 3.0 (p < 0.001), Online CBT group (Group #3) scores 
decreased from 15.4 ±  3.8 to 3.4 ±  2.7 (p <  0.01), and the 
Stepped-care pathway group (Group #4) scores decreased 
from 15.3 ± 3.6 to 5.4 ± 2.8 (p < 0.05). However, there were no 
statistically significant differences between any of the groups in 
the amount of change in PHQ-9 scores at either 6 or 12 weeks 
(Figure 4).
It should also be noted that among the 889 patients who 
completed both baseline ratings and again at 12 weeks, a total of 
21 individuals had PHQ-9 scores ≥10, but whose scores were less 
than 10 at baseline. This would suggest that there was an inci-
dence rate of depression of 2.4% over 12 weeks (an approximately 
annual incidence rate of 10%) in this sample.
FigUre 2 | Patient numbers in each group during study. This shows the number of patients randomized to each of four groups, and the number who were 
followed up at 12 weeks (and the percentage) for both the total group and those who were depressed. Group #1 was the Control group; Group #2 was screening 
followed by treatment-as-usual (TAU); Group #3 was screening followed by TAU and online cognitive behavioral therapy (CBT); and Group #4 was the screening 
followed by Stepped-care. Note that not all clinics offered the Stepped-care option that is why fewer patients were randomized to this group.
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DiscUssiOn
We are not aware of another randomized study in primary care 
that has controlled for screening in the same manner as we have 
done. This is important to note, as the findings from our study 
do not support suggestions that screening for depression in 
primary care improves outcomes, at least as measured by PHQ-9 
depression scores. While this was not the goal of the study, or 
part of our hypotheses, it is important to note as it has significant 
implications. Additionally, the present findings show that in the 
vast majority of cases of depression in primary care resolution 
occurs over a 12-week period, even in the absence of screening 
information passed onto the patient of physician to identify the 
presence of depression. Our other finding was that the type of 
intervention also appeared to make little difference and does not 
support the use of complex Stepped-care pathways compared to 
usual care. However, the clinics that took part were self-selected, 
and it is conceivable that these primary care practices practice 
an evidence-based approach and have a high degree of aware-
ness for the risk of depression occurring in their patients, and 
thus screening would be unlikely to identify additional patients 
and many of the physicians may already be carrying out best 
practices. Additionally, as we did not have access to the clinical 
charts, we could not determine whether or not patients who were 
depressed in the Control group were in fact already detected by 
physicians.
One other point to note was that in reality there was very little 
difference between Group #2 (screening followed by TAU) and 
Group #3 (screening followed by TAU but with the addition of 
online CBT). This is because, despite our best efforts, uptake of 
the online CBT was very low. While a total of 25 of the potential 29 
depressed patients in this group logged on, less than 5 completed 
more than 1 CBT session, and none of the patients completed the 
entire program. Thus, the possible potential impact of the CBT 
approach was limited. These rather disappointing results are 
similar to others, which have found that unless there is “guided” 
CBT (i.e., a person encouraging an individual on a repeated basis) 
very few individuals complete online CBT programs for depres-
sion (43, 49–52).
In terms of improvements, it is well recognized that many 
patients who have depression in primary care improve spon-
taneously, with one review estimating that 23% of untreated 
depression patients in primary care will remit within 12 weeks, 
with higher remission rates occurring in those who have milder 
depressive illness (59). The fact that the mean PHQ-9 scores in 
all the groups were quite low at baseline (13.7–14.5) would be 
consistent with this.
Other Methodological issues and study 
limitations
Despite the fact that this is a randomized controlled study, there 
were significant limitations that require further research before 
any definitive recommendations can be made. The first issue is 
that this study took place in only two clinics, and not the five 
we had intended. A second concern is that, particularly in the 
FigUre 3 | changes in mean 9-item Patient health Questionnaire (PhQ-9) scores for total group. The mean scores from baseline to 12 weeks decreased 
across the entire group, but these were only statistically significant for the Control Group #1 (***p < 0.001) and the Screening and Treatment-as-usual Group #2 
(*p < 0.05). There were no statistically significant changes for either Group #3 or Group #4. The number of patients in each group at both baseline and 12 weeks is 
shown in Figure 1.
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clinic who had training on the Stepped-care pathway, they could 
have integrated many of those approaches to their practice as 
part of their TAU, thus decreasing the apparent impact of the 
Stepped-care approach. Another issue with the data is that not 
only was the Stepped-care group much smaller than the others 
but it also had by far the lowest retention rates for the study. We 
are uncertain why this is the case, but it is possible that those who 
did not have a 12-week follow-up were doing better than those 
who were followed up. It is also important to note that our goal 
was to recruit patients from five separate clinics. However, despite 
approaching multiple clinics within the region we were able to 
only involve two clinics, only one of which was willing to take part 
in the Stepped-care pathway. This is why there were fewer patients 
randomized to this group (Group #4). Reasons from potential 
clinics as to why they were unwilling to take part in the research 
study included the following:
• Concerns about clinic staff resources being required was a 
major worry for many clinics. Many clinicians were also con-
cerned that taking part in the study would interfere with the 
flow of patients.
• Clinics felt that their mental health teams were already too 
busy and were concerned the study would identify more 
patients needing treatment. They felt they could not manage 
more referrals, even if it was seen as a chance to prevent 
depression from worsening.
• Clinics were burdened with other priorities including other 
multiple quality improvement initiatives that were prioritized 
by clinic staff.
• Concerns around managing information on an ongoing basis 
was a concern, particularly as larger clinics have several phy-
sicians who may interact with the patient and can be hard to 
standardize the care approach
There were also specific concerns expressed about the Stepped-
care pathway:
• The Stepped-care pathway requires initial and ongoing 
training—seen as time intensive for staff that are already busy 
with many priorities
• Stepped-care pathway requires repeated use of standardized 
tools and approaches, including specific advice regarding 
which medications would be used for specific patients, thus 
decreasing physician independence.
• Clinics felt that new evidence was always coming out, making 
it difficult to keep a detailed Stepped-care pathway up-to-date.
It should also be noted that these were “convenience” samples, 
i.e., only patients who came to the family practice were eligible. 
In terms of the randomization approach, since the waiting areas 
were open, it was likely that other patients in the waiting room 
would be aware of the study. For this reason, it was determined 
that randomization should occur per day, and not per patient. 
FigUre 4 | changes in mean 9-item Patient health Questionnaire-9 (PhQ-9) scores for those patients who were depressed at baseline. It can be seen 
that the mean PHQ-9 scores decreased significantly at both 6 and 12 weeks in all groups. However, there were no statistically significant differences between any of 
the groups at either time point. *p < 0.05 compared to baseline, **p < 0.01 compared to baseline, ***p < 0.001 compared to baseline.
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Thus, all patients who attended a specific clinic on an individual 
day would all be entered into the same group. This would avoid 
any possible issues where one patient in the waiting room, for 
example, was offered the opportunity to take part in online CBT 
while another was not. Another aspect that needs consideration 
is that after a period of time (usually 4–6  weeks) many of the 
patients coming to a specific clinic were those who had already 
come in the previous period, and therefore were not eligible. For 
this reason, recruitment rates decreased over time at each clinic 
and to address this recruitment alternated between clinics for a 
6-week period (i.e., patients were only recruited at specific clinics 
for 6-week periods, before returning to the same clinic after a 
similar time period). Additionally, we did not have the resources 
to examine the medical charts of the patients who took part in 
the study. Therefore, we were not able to compare medication 
use, actual diagnosis, other medical diagnosis, or have access to 
demographic data. All of these may have helped understand the 
study population in more detail.
It can also be seen that making patients aware of the study, 
completing the informed consent process, and then completing 
the forms, took time. There were therefore many patients who 
expressed willingness to take part, and who started to complete 
the PHQ-9, but before completion they were called in for their 
appointment. In all such cases, the patient stopped entering data 
immediately and was not included in the study.
In terms of follow-up calls, our protocol only allowed an initial 
call and a maximum of only two follow-up calls, which all had 
to be carried out over a few days. It is possible, therefore, that 
different calling protocol, or use of other communication tools, 
may have led to higher follow-up rates at 12 weeks.
cOnclUsiOn
Despite the methodological issues, the present study was car-
ried out in a relatively large group of patients who were then 
followed up for a meaningful period. Despite this, there was 
no evidence suggesting either that screening enhanced depres-
sion outcomes, or that any specific treatment intervention 
was more effective than TAU. Supporting the relevance of the 
study, our findings that the annual incidence for depression 
was approximately 10% are consistent with some other studies 
(55), although one recent study found an incidence rate of only 
5% (60).
In conclusion, the findings from the present randomized 
controlled study in family practice suggest that most patients 
who have depressive symptoms have mild depression, much of 
which will resolve spontaneously. Our findings did not support 
any additional benefit for screening of patients for depression, or 
the use of specific treatment approaches when compared to TAU. 
Nonetheless, given the major burden of depression, its impact 
upon medical health as well as psychological health, and the key 
desire to minimize its occurrence, as well as the limitations of 
the present research, further randomized well controlled research 
studies in this area are critical.
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